Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy such as brostallicin use different ways to stop cancer
cells from dividing so they stop growing or die.
PURPOSE: Phase I/II trial to study the effectiveness of brostallicin in treating patients who
have recurrent or refractory multiple myeloma.